BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $126.00
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target boosted by equities researchers at Piper Sandler from $122.00 to $126.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price objective points to a potential upside of 84.62% from […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target boosted by equities researchers at Piper Sandler from $122.00 to $126.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price objective points to a potential upside of 84.62% from […]
